Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Managing MS in a changing treatment landscape.

Duddy M, Haghikia A, Cocco E, Eggers C, Drulovic J, Carmona O, Zéphir H, Gold R.

J Neurol. 2011 May;258(5):728-39. doi: 10.1007/s00415-011-6009-x. Epub 2011 Mar 25. Review.

PMID:
21437661
2.
3.

[Current treatment of multiple sclerosis].

Csépány T.

Lege Artis Med. 2011 Feb;21(2):97-104. Review. Hungarian.

PMID:
21710707
4.

New oral drugs for multiple sclerosis.

Gasperini C, Ruggieri S.

Neurol Sci. 2009 Oct;30 Suppl 2:S179-83. doi: 10.1007/s10072-009-0146-3. Review.

PMID:
19882371
5.

Current disease-modifying therapies in multiple sclerosis.

Kieseier BC, Hartung HP.

Semin Neurol. 2003 Jun;23(2):133-46. Review. Erratum in: Semin Neurol. 2003 Sep;23(3):343.

PMID:
12894379
6.

Current and future disease-modifying therapies in multiple sclerosis.

Lim SY, Constantinescu CS.

Int J Clin Pract. 2010 Apr;64(5):637-50. doi: 10.1111/j.1742-1241.2009.02261.x. Review.

PMID:
20456216
7.

[Multiple sclerosis: current therapies and future perspectives].

Matsushita T.

Nihon Rinsho. 2011 Nov;69(11):2077-86. Review. Japanese.

PMID:
22111333
8.

Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.

Gonsette RE.

Expert Opin Pharmacother. 2007 Jun;8(8):1103-16. Review.

PMID:
17516874
9.

Current disease-modifying treatment of multiple sclerosis.

Derwenskus J.

Mt Sinai J Med. 2011 Mar-Apr;78(2):161-75. doi: 10.1002/msj.20239. Review.

PMID:
21425262
10.

New disease-modifying therapies and new challenges for MS.

Yadav V, Bourdette D.

Curr Neurol Neurosci Rep. 2012 Oct;12(5):489-91. doi: 10.1007/s11910-012-0295-2.

PMID:
22760478
11.

First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Johnston J, So TY.

Drugs. 2012 Jun 18;72(9):1195-211. doi: 10.2165/11634010-000000000-00000. Review.

PMID:
22642799
12.

Fingolimod for the treatment of relapsing multiple sclerosis.

Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K.

Expert Rev Neurother. 2011 Feb;11(2):165-83. doi: 10.1586/ern.10.193. Epub 2010 Dec 16. Review.

PMID:
21158700
13.

Emerging oral agents for multiple sclerosis.

Fox EJ.

Am J Manag Care. 2010 Sep;16(8 Suppl):S219-26. Review.

14.

Current approved options for treating patients with multiple sclerosis.

Rizvi SA, Agius MA.

Neurology. 2004 Dec 28;63(12 Suppl 6):S8-14. Review.

PMID:
15623672
15.

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.

16.

Oral therapy for multiple sclerosis--sea change or incremental step?

Carroll WM.

N Engl J Med. 2010 Feb 4;362(5):456-8. doi: 10.1056/NEJMe0912019. Epub 2010 Jan 20. No abstract available.

PMID:
20089958
17.

[An update on the treatment options for multiple sclerosis].

Niino M.

Brain Nerve. 2012 Dec;64(12):1421-6. Review. Japanese.

PMID:
23209069
18.

Update on emerging therapies for multiple sclerosis.

Yiu EM, Banwell B.

Expert Rev Neurother. 2010 Aug;10(8):1259-62. doi: 10.1586/ern.10.98.

PMID:
20662750
19.

Emerging oral drugs for multiple sclerosis.

Gasperini C, Cefaro LA, Borriello G, Tosto G, Prosperini L, Pozzilli C.

Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77. doi: 10.1517/14728214.13.3.465 . Review.

PMID:
18764723
20.

[Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].

Hecht B.

Med Monatsschr Pharm. 2010 Apr;33(4):120-30; quiz 131-2. Review. German.

PMID:
20429402

Supplemental Content

Support Center